Please login to the form below

Not currently logged in

Lilly and Sanford-Burnham reveal immunology collaboration

Will aim to discover and develop therapies in the field

Eli Lilly HQ 

Eli Lilly and Sanford-Burnham Medical Research Institute are to collaborate to discover and develop immunological therapies.

Sanford-Burnham, a non-profit medical research institute, and Lilly will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases including lupus and inflammatory bowel disease (IBS).

The research collaboration will be co-chaired by Thomas Burnol, senior VP of biotechnology and immunology research at Lilly, alongside Carl Ware, director of infectious and inflammatory diseases centre at Sanford-Burnham.

Burnol commented: “Immunology is an important research area of focus for Lilly and through this exciting collaboration with Sanford-Burnham, our scientists can discover and develop new medicines together in a seamless way that takes advantage of each group in a family of key targets.”

In the field of immunology, Lilly currently has seven molecules in the pipeline for conditions such as psoriasis, rheumatoid arthritis, lupus and IBS. 

Sanford-Burnham's experience in the area focuses on cell communication pathways that control the development of lymphocytes, innate and adaptive immune responses and inflammation, leading to the development of treatments for immunological and inflammatory diseases and cancer.

Perry Nisen, CEO at Sanford-Burnham, said: "The Lilly-Sanford-Burnham collaboration is precedent setting in scope and its potential to advance discoveries to the patient more efficiently. 

"By combining the deep knowledge of human biology and disease mechanisms among Sanford-Burnham scientists, in particular our expertise in the field of checkpoint regulators in the immune system, and Lilly's leadership position in the development of biologics and large molecules, we are forging the path to develop the next generation of transformative treatments for autoimmune disease."

Article by
Kirstie Pickering

15th May 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...